Previous Nav
Net Change on 19-05-2022
PersonalFN Rating
Category
Assets (Cr.)
Expense Ratio
Fund House
Launch Date
Benchmark
Minimum Investment (₹)
Minimum Addl Investment (₹)
Exit Load (%)
Minimum SIP Investment (₹)
Minimum STP Investment (₹)
Minimum SWP Investment (₹)
52 Week Low Nav (₹)
52 Week Low Nav Date
52 Week High Nav (₹)
52 Week High Nav Date
Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised
Sun Pharmaceutical Industries Ltd.
Divi's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
Cipla Ltd.
Apollo Hospitals Enterprise Ltd.
Aurobindo Pharma Ltd.
JB Chemicals & Pharmaceuticals Ltd.
IPCA Laboratories Ltd.
Torrent Pharmaceuticals Ltd.
Gland Pharma Ltd.
Alkem Laboratories Ltd.
Laurus Labs Ltd.
Syngene International Ltd.
Abbott India Ltd.
Vinati Organics Ltd.
Tata Steel Ltd.
Pfizer Ltd.
Biocon Ltd.
Jubilant Ingrevia Ltd.
Rossari Biotech Ltd.
Aster DM Healthcare Ltd.
Zydus Lifesciences Ltd.
Metropolis Healthcare Ltd.
ICICI Lombard General Insurance Company Ltd.
Indoco Remedies Ltd.
HDFC Life Insurance Company Ltd.
Natco Pharma Ltd.
Lupin Ltd.
TREPS
Net Receivable / Payable
Pharmaceuticals & Drugs
Hospital & Healthcare Services
Chemicals
Miscellaneous
Insurance
Steel & Iron Products
Cash
Equity
IDBI Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to IDBI Mutual Fund. It was launched on 28-Feb-2019 and currently has an AUM of ₹67.07 crore. IDBI Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and S&P BSE Health Care - TRI as secondary index.
The NAV of IDBI Healthcare Fund ended down ₹-0.35(-2.06%)yesterday to ₹16.6.
Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and
The IDBI Healthcare Fund is managed by Alok Ranjan .
5th floor, Mafatlal Centre, Nariman Point Mumbai - 400021